P-X Ding1, Y-D Li, X-W Han, G Wu, S-F Shui, Y-L Wang. 1. Department of Radiology, The First Affiliated Hospital, Zhengzhou University, Zhengzhou, Henan Province, China.
Abstract
PURPOSE: This study was undertaken to evaluate the safety and feasibility of thrombolytic urokinase treatment after predilation in patients with Budd-Chiari syndrome (BCS) with chronic inferior vena cava (IVC) thrombosis. MATERIALS AND METHODS: Between December 2006 and September 2009, 13 consecutive BCS patients with chronic IVC thrombosis were treated with continuous urokinase infusion after predilation and subsequent (i.e. after thrombus resolution) IVC dilation with a 30-mm dilator. The procedural technical and angiographic, and ultrasonic results, as well as mortality, morbidity and the final clinical outcome, were evaluated immediately after the treatment or at 1 week and 1, 3, 6 and 12 months and then annually thereafter. RESULTS: The immediate and long-term procedural technical outcome was successful in all patients. Follow-up inferior vena cavagrams demonstrated complete resolution of the chronic IVC thrombi and full IVC patency, without occurrence of pulmonary embolism at any time during the study. Colour-Doppler ultrasound (US) follow-up for 16.92 months (± 12.04) showed full patency of the IVC, without thrombosis, restenosis or reobstruction, in all patients and resolution of all clinical symptoms. All patients were alive at the time of this report. CONCLUSIONS: Our preliminary results indicate that thrombolysis with continuous infusion of urokinase after predilation is a safe and feasible approach for treating BCS patients with chronic IVC thrombosis.
PURPOSE: This study was undertaken to evaluate the safety and feasibility of thrombolytic urokinase treatment after predilation in patients with Budd-Chiari syndrome (BCS) with chronic inferior vena cava (IVC) thrombosis. MATERIALS AND METHODS: Between December 2006 and September 2009, 13 consecutive BCS patients with chronic IVC thrombosis were treated with continuous urokinase infusion after predilation and subsequent (i.e. after thrombus resolution) IVC dilation with a 30-mm dilator. The procedural technical and angiographic, and ultrasonic results, as well as mortality, morbidity and the final clinical outcome, were evaluated immediately after the treatment or at 1 week and 1, 3, 6 and 12 months and then annually thereafter. RESULTS: The immediate and long-term procedural technical outcome was successful in all patients. Follow-up inferior vena cavagrams demonstrated complete resolution of the chronic IVC thrombi and full IVC patency, without occurrence of pulmonary embolism at any time during the study. Colour-Doppler ultrasound (US) follow-up for 16.92 months (± 12.04) showed full patency of the IVC, without thrombosis, restenosis or reobstruction, in all patients and resolution of all clinical symptoms. All patients were alive at the time of this report. CONCLUSIONS: Our preliminary results indicate that thrombolysis with continuous infusion of urokinase after predilation is a safe and feasible approach for treating BCS patients with chronic IVC thrombosis.
Authors: Juan Carlos Garcia-Pagán; Mathis Heydtmann; Sebastian Raffa; Aurélie Plessier; Sarwa Murad; Federica Fabris; Giovanni Vizzini; Juan Gonzales Abraldes; Simon Olliff; Antonio Nicolini; Angelo Luca; Massimo Primignani; Harry L A Janssen; Dominique Valla; Elwyn Elias; Jaume Bosch Journal: Gastroenterology Date: 2008-05-21 Impact factor: 22.682
Authors: Sarwa Darwish Murad; Aurelie Plessier; Manuel Hernandez-Guerra; Federica Fabris; Chundamannil E Eapen; Matthias J Bahr; Jonel Trebicka; Isabelle Morard; Luc Lasser; Joerg Heller; Antoine Hadengue; Philippe Langlet; Helena Miranda; Massimo Primignani; Elwyn Elias; Frank W Leebeek; Frits R Rosendaal; Juan-Carlos Garcia-Pagan; Dominique C Valla; Harry L A Janssen Journal: Ann Intern Med Date: 2009-08-04 Impact factor: 25.391